A Study of MK-2060 in Healthy Participants (MK-2060-016)
Sponsored by Merck Sharp & Dohme LLC
About this trial
Last updated 8 months ago
Study ID
2060-016
Status
Recruiting
Type
Interventional
Phase
Phase 1
Placebo
Yes
Accepting
18 to 50 Years
All
Trial Timing
Ended 11 days ago
What is this trial about?
The goal of the study is to learn about the safety of MK-2060 and if people tolerate it
when MK-2060 is given in different forms.
What are the participation requirements?
Inclusion Criteria
The key inclusion criteria include but are not limited to the following: - Is in good health before randomization - Has a body mass index (BMI) between ≥18 and ≤32 kg/m^2, inclusive
Exclusion Criteria
The key exclusion criteria include but are not limited to the following: - Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases - Has a history of cancer
Locations
Location
Status
Recruiting
Recruiting